Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE versus CALDEROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPOTRIENE versus CALDEROL.
CALCIPOTRIENE vs CALDEROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
None Documented
None Documented
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Category C
Category C
Vitamin D Analog
Vitamin D Analog